Indivior Pharmaceuticals, Inc. Common Stock
INDV
$30.54
-5.48%
Indivior Pharmaceuticals is a specialty pharmaceutical company singularly focused on developing and commercializing treatments for opioid use disorder (OUD), operating within the specialty and generic drug manufacturing industry. The company is a recognized leader in the OUD treatment space, distinguished by its portfolio of buprenorphine-based medications, including the long-acting injectable Sublocade and the sublingual film Suboxone. The current investor narrative is dominated by the company's strong financial recovery and growth trajectory, as evidenced by a significant year-over-year revenue increase in its most recent quarter, alongside a strategic focus on expanding its long-acting treatment portfolio to drive sustainable growth and market share.…
INDV
Indivior Pharmaceuticals, Inc. Common Stock
$30.54
Investment Opinion: Should I buy INDV Today?
Rating: Hold. The core thesis is that INDV is a high-risk, high-potential turnaround story where spectacular operating progress is being undermined by critical financial weaknesses, recommending caution until cash flow turns sustainably positive.
Supporting evidence for this neutral stance includes the company's strong Q4 revenue growth of 19.7% YoY to $358M and net margin of 28.8%, which support the bull case. The forward P/E of 8.87x is deeply discounted relative to this growth, and analyst EPS estimates average $4.15, implying significant earnings growth. However, this is counterbalanced by the severe debt-to-equity ratio of -3.58, negative trailing FCF of -$85.6M, and the stock's high volatility (beta 1.205), which collectively elevate risk beyond what the valuation discount justifies.
The thesis would upgrade to a Buy if the company reports consecutive quarters of positive operating cash flow, demonstrating a path to financial sustainability, and if the forward P/E remains below 10x. It would downgrade to a Sell if quarterly revenue growth decelerates below 10% YoY, if cash burn accelerates, or if the stock breaks below key technical support near $28.78 on high volume. Relative to its own volatile history, the stock appears fairly valued given the binary risk/reward, but is unequivocally undervalued on forward earnings if—and only if—the financial distress is resolved.
Sign up to view all
INDV 12-Month Price Forecast
INDV presents a classic 'show me' story. The operational momentum is undeniable, but the financial statements reveal a company still in a precarious turnaround phase. The AI stance is neutral with medium confidence because the outcome is binary and hinges on cash flow conversion. The stock is not a buy until it demonstrates an ability to fund its own growth. The stance would upgrade to bullish on confirmation of sustained positive free cash flow for two consecutive quarters. It would turn bearish if revenue growth decelerates below 10% or if the company announces an equity offering to shore up its balance sheet.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Indivior Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $39.70 and implied upside of +30.0% versus the current price.
Average Target
$39.70
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$24 - $40
Analyst target range
Analyst coverage for INDV is limited, with only two analysts providing estimates, which is typical for a smaller specialty pharmaceutical company and can lead to higher volatility and less efficient price discovery. The consensus among the limited coverage appears bullish, with recent institutional ratings from firms like HC Wainwright, Piper Sandler, and Craig-Hallum consistently maintaining 'Buy' or 'Overweight' recommendations, though a formal consensus recommendation and average target price are not available in the provided data. The analyst revenue estimates for the coming year show a range from approximately $1.34 billion to $1.42 billion, with an average of $1.38 billion, while EPS estimates range from $4.01 to $4.32; this relatively tight range on revenue, coupled with the unanimous bullish ratings from covering firms, suggests a degree of conviction in the company's near-term growth outlook, though the very small analyst pool means this sentiment is not broadly representative of the entire Street.
Bulls vs Bears: INDV Investment Factors
The investment case for INDV is a stark battle between compelling operating momentum and severe financial fragility. The bull side currently presents stronger near-term evidence, anchored by explosive revenue growth (19.7% YoY), soaring profitability (28.8% net margin), and a seemingly cheap forward P/E of 8.87x. However, the bear case is grounded in fundamental solvency risks, with a debt-to-equity ratio of -3.58 and negative operating cash flow of -$221 million in the latest quarter. The single most important tension is the disconnect between reported accounting profits and actual cash burn. If the company can translate its high-margin revenue growth into sustained positive free cash flow, the stock could re-rate significantly higher. If the cash burn persists or worsens, the seemingly cheap valuation will prove to be a value trap, and the negative equity structure could lead to severe dilution or financial restructuring.
Bullish
- Explosive Revenue Growth & Profitability: Q4 2025 revenue of $358 million grew 19.7% YoY, accelerating sequentially from Q3 ($314M) and Q2 ($302M). This growth is highly profitable, with a Q4 net margin of 28.8% and a gross margin of 82.1%, demonstrating strong pricing power and operational leverage.
- Compelling Forward Valuation: The forward P/E ratio of 8.87x, based on analyst EPS estimates of $4.15, is exceptionally low for a company with this growth profile. This suggests the market is pricing in minimal future growth, creating a significant valuation gap if execution continues.
- Strong Technical Uptrend Intact: Despite a recent pullback, the stock is up 241.6% over the past year and remains at 80.3% of its 52-week range ($8.69 to $38.00). The long-term trend remains powerfully bullish, with the stock having significantly outperformed the SPY by 212 percentage points over the last year.
- Analyst Conviction in Growth: The limited analyst coverage is unanimously bullish (Buy/Overweight ratings from HC Wainwright, Piper Sandler, Craig-Hallum). Revenue estimates for the coming year are tightly clustered around $1.38 billion, indicating confidence in the top-line trajectory.
Bearish
- Severe Financial Distress Signals: The balance sheet shows a debt-to-equity ratio of -3.58 and negative shareholder equity, a major red flag. Furthermore, trailing free cash flow is -$85.6 million and Q4 operating cash flow was -$221 million, indicating the company is burning cash despite reported profits.
- Parabolic Rally Followed by Sharp Correction: The stock is down 14.5% YTD, 13.8% over 3 months, and 7.0% over 1 month, signaling a clear loss of momentum and potential trend exhaustion after a 241.6% surge. This high volatility (beta of 1.205) increases downside risk during market corrections.
- Extreme Dependence on Future Execution: The entire bullish thesis hinges on the company delivering on analyst EPS estimates of $4.15 to justify its forward P/E of 8.87x. Any stumble in revenue growth (currently 19.7% YoY) or margin compression would shatter the low-valuation narrative.
- Limited Analyst Coverage & Liquidity Risk: With only two analysts providing estimates, price discovery is less efficient and the stock is more susceptible to sharp moves on limited news. A short ratio of 3.93 also indicates a significant portion of the float is sold short, reflecting skepticism.
INDV Technical Analysis
The stock is in a powerful, sustained uptrend over the past year, evidenced by a staggering 241.61% one-year price appreciation, yet it is currently experiencing a significant pullback from recent highs. As of the latest close at $30.54, the price sits approximately 80.3% of its 52-week range ($8.69 to $38.00), indicating it has retreated meaningfully from its peak but remains well above its lows, suggesting a potential consolidation phase after a parabolic move. Recent momentum has turned sharply negative, with the stock down 6.98% over the past month and 13.83% over the past three months, a stark divergence from the longer-term uptrend that signals a period of profit-taking and potential trend exhaustion following the explosive rally that peaked in December 2025. Key technical levels are clearly defined, with immediate support at the 52-week low of $8.69 and major resistance at the 52-week high of $38.00; a decisive break above $38 would signal a resumption of the bull trend, while a sustained move below the recent lows near $28.78 could indicate a deeper correction. With a beta of 1.205, the stock is approximately 20% more volatile than the broader market (SPY), which is evident in its dramatic 28.43% six-month gain against SPY's 4.05% rise, underscoring its higher-risk, higher-reward profile that requires careful risk management.
Beta
1.21
1.21x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$9-$38
Price range past year
Annual Return
+241.6%
Cumulative gain past year
| Period | INDV Return | S&P 500 |
|---|---|---|
| 1m | -7.0% | +2.6% |
| 3m | -13.8% | -2.3% |
| 6m | +28.4% | +2.6% |
| 1y | +241.6% | +27.3% |
| ytd | -14.5% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INDV Fundamental Analysis
Indivior is demonstrating a robust revenue growth trajectory, with Q4 2025 revenue reaching $358 million, representing a 19.73% year-over-year increase, and this follows a sequential acceleration from $314 million in Q3 and $302 million in Q2. The company has returned to strong profitability, reporting net income of $103 million for Q4 2025, which translates to a net margin of 28.77%, and this profitability is supported by an exceptionally high gross margin of 82.12%, indicating significant pricing power and efficient manufacturing for its specialty pharmaceutical products. The balance sheet and cash flow present a mixed picture; while the company shows a strong Return on Assets (ROA) of 19.22%, it has a negative Return on Equity (ROE) of -2.14 and a concerning debt-to-equity ratio of -3.58, which is an artifact of negative shareholder equity. Furthermore, trailing twelve-month free cash flow is negative at -$85.6 million, and the most recent quarterly operating cash flow was -$221 million, indicating the company is currently consuming cash to fund operations, which elevates financial risk despite the impressive top-line growth and margins.
Quarterly Revenue
$358000000.0B
2025-12
Revenue YoY Growth
+0.19%
YoY Comparison
Gross Margin
+0.82%
Latest Quarter
Free Cash Flow
$-85619260.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INDV Overvalued?
Given the company's positive net income of $103 million in its latest quarter, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio stands at 21.36x, while the forward P/E is significantly lower at 8.87x, indicating the market expects a substantial increase in earnings over the next year, aligning with analyst EPS estimates averaging $4.15. Compared to sector averages, the stock's trailing P/E of 21.36x and Price-to-Sales (P/S) ratio of 3.62x are not directly comparable without a provided industry benchmark, but the forward P/E of 8.87x suggests a valuation that may be reasonable if the projected earnings growth materializes. Historically, the stock's own P/E ratio has been highly volatile, ranging from deeply negative figures during periods of loss to over 80x; the current trailing P/E of 21.36x is within a more normalized band compared to recent history (e.g., 10.89x at the end of Q4 2025), suggesting the market is pricing in sustained profitability rather than the extreme optimism or pessimism seen in prior periods.
PE
21.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -6x~81x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute and center on liquidity and capital structure. Despite a 28.8% net margin, the company reported -$221 million in operating cash flow for Q4 2025, with trailing FCF at -$85.6 million, indicating profits are not converting to cash. The balance sheet is technically insolvent, with negative shareholder equity and a debt-to-equity ratio of -3.58, which could limit financial flexibility and raise refinancing risks. Revenue, while growing, remains concentrated in buprenorphine-based treatments, making the company vulnerable to any pricing pressure, generic competition, or clinical setbacks for its key products Sublocade and Suboxone.
Market & Competitive Risks include valuation compression given the stock's 241.6% run-up over the past year and its current pullback from highs. Trading at a forward P/E of 8.87x, the market is pricing in near-perfect execution; any earnings miss could trigger a severe multiple contraction. The stock's high beta of 1.205 makes it 20% more volatile than the market, amplifying downside during sector rotations or bear markets. Competitive and regulatory risks in the opioid treatment space are ever-present, and the limited analyst coverage (only 2) means sentiment can shift violently on single data points or news events.
Worst-Case Scenario involves a continuation of cash burn leading to a liquidity crisis, forcing a dilutive equity raise or debt restructuring at unfavorable terms. This could be triggered by a slowdown in Sublocade adoption or unexpected competitive entry. In this adverse scenario, the stock could retrace a significant portion of its gains, testing its 52-week low of $8.69. From the current price of $30.54, this represents a catastrophic downside of approximately -71.5%. A more realistic bear-case target, aligning with a breakdown of the growth narrative, could be in the mid-teens, representing a -50% to -60% decline.
FAQ
The key risks, in order of severity, are: 1) Financial Liquidity Risk: The company is burning cash (-$221M operating cash flow in Q4) and has negative shareholder equity, risking a capital crisis. 2) Execution Risk: The entire bullish thesis depends on hitting analyst EPS of $4.15; any miss could crater the low P/E narrative. 3) Competitive/Market Risk: Revenue is concentrated in OUD treatments, leaving it exposed to new competitors or pricing pressure. 4) Volatility Risk: With a beta of 1.205 and limited analyst coverage, the stock is prone to extreme price swings on minimal news.
The 12-month forecast is highly bifurcated. The base case (50% probability) sees the stock trading between $30 and $38 as it meets growth estimates but struggles with cash flow, aligning with the upper end of its recent trading range. The bull case (30% probability) targets $38 to $45+ on sustained cash flow positivity and multiple expansion. The bear case (20% probability) warns of a drop to $15-$25 if financial distress escalates and growth stalls. The most likely outcome is the base case, contingent on the company continuing its revenue growth trajectory without a financial accident.
INDV is a tale of two valuations. On a forward earnings basis, it appears deeply undervalued at a P/E of 8.87x relative to its growth rate. However, on a cash flow basis, it is catastrophically overvalued with a P/CF ratio of -166x due to massive cash burn. Compared to its own history, the trailing P/E of 21.36x is within a normalized band after a period of extreme volatility. The market is currently valuing it as a 'show me' story, assigning a low earnings multiple that discounts the very real risk of financial distress. It is fairly valued for the binary risk it presents.
INDV is a high-risk, high-reward proposition, not a universally 'good' buy. For aggressive investors comfortable with distressed balance sheets, the potential upside is significant, with a forward P/E of only 8.87x against 19.7% revenue growth. However, the severe risks—negative cash flow, negative equity, and high volatility—make it unsuitable for most investors. It could be a good buy for a speculative portion of a portfolio if you believe the company will imminently fix its cash flow problems, but it is a very poor buy for anyone seeking stability or safety.
INDV is unsuitable for short-term trading for all but the most sophisticated traders due to its high volatility (beta 1.205) and low liquidity. It is a speculative long-term investment, but with a critical caveat: the 'long-term' thesis is only valid if the company survives its near-term financial challenges. Investors should be prepared to hold for a minimum of 2-3 years to see if the turnaround to sustainable profitability and cash generation is achieved. This is not a set-and-forget investment; it requires active monitoring of quarterly cash flow statements.